BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:FcRn\, Fcγ\, and IgG studies have been propelled by drug devel
 opers recently after Argenx’s potential FDA’s approval of first-in-class 
 FcRn antagonist efgartigimod\, AstraZeneca-Alexion’s $39 billion deal\, a
 nd positive clinical updates from UCB’s Rozanolixizumab. Successful modul
 ation of the Fc pathways and optimized IgG antibodies have proven clinica
 l utility and demonstrate significant therapeutic potential with more pla
 yers poised to bring their candidates through clinic.\n\nThe 2nd Fc Recep
 tor &amp\; IgG Targeted Therapies Summit is the only dedicated meeting to
  bring you the most up-to-date with clinical and commercial developments 
 on pioneering strategies to harness the full potential of FcRs.\n\nThis 3
 -day summit will return in 2022 with a fresh speaker line-up\, 2 dedicate
 d streams to offer you the A-Z of Fc receptors and IgG targeting. Bringin
 g together exclusive data on targeting FcRn and FcyRs\, and the engineeri
 ng strategies employed to harness the FcR-IgG interaction to yield clinic
 al efficacy. Hear from industry leaders such as FDA\, Genentech\, Alexion
 \, UCB\, Argenx\, Genmab\, and more as they modulate the dynamic behavior
  of IgG to fast-track candidates to address unmet medical needs.\n\nJoin 
 130+ experts in Boston to:- Discuss translating novel Fc biology insights
  to innovative drug design- Explore FcR antagonists\, Fc fusion proteins\
 , and novel antibodies- Move confidently to clinic with predictive PKPD a
 ssessments from best-in-class cellular assays- Enhance the therapeutic po
 tential of antibodies with next-gen engineering strategies to minimize im
 munogenicity\n
DTEND:20220428T160000
DTSTAMP:20260512T232301Z
DTSTART:20220426T090000
LOCATION:Hilton Boston Back Bay\, 40 Dalton Street\, Boston\, Massachusett
 s\, 02115\,
SEQUENCE:0
SUMMARY:FcRn\, Fcγ\, and IgG studies have been propelled by drug developer
 s recently after Argenx’s potential FDA’s approval of first-in-class FcRn
  antagonis...
UID:a7d4af35-1ed6-4afb-97bb-447b9f9ebfee
END:VEVENT
END:VCALENDAR